Patents by Inventor Grant McFadden

Grant McFadden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF WOUND HEALING WITH SERP-1 POLYPEPTIDES
    Publication number: 20250235581
    Abstract: Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.
    Type: Application
    Filed: April 8, 2025
    Publication date: July 24, 2025
    Inventors: Alexandra LUCAS, Liqiang ZHANG, Jordan YARON, Grant MCFADDEN
  • Methods of wound healing with Serp-1 polypeptides
    Patent number: 12296066
    Abstract: Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: May 13, 2025
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Alexandra Lucas, Liqiang Zhang, Jordan Yaron, Grant McFadden
  • COVID-19 VACCINE BASED ON THE MYXOMA VIRUS PLATFORM
    Publication number: 20230151387
    Abstract: The present invention provides myxoma viral vectors that encode severe acute respiratory syndrome coronavirus 2 antigens and that can facilitate expression and secretion of virus-like particles (VLPs). Also provided are methods of making said VLPs in mammalian cells and using said VLPs and myxoma viral vectors to induce an immune response in a subject.
    Type: Application
    Filed: April 2, 2021
    Publication date: May 18, 2023
    Inventors: Grant MCFADDEN, Mohammed Masmudur RAHMAN, Brenda G. HOGUE
  • METHODS OF WOUND HEALING WITH SERP-1 POLYPEPTIDES
    Publication number: 20210369910
    Abstract: Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.
    Type: Application
    Filed: May 17, 2019
    Publication date: December 2, 2021
    Inventors: Alexandra LUCAS, Liqiang ZHANG, Jordan YARON, Grant McFADDEN
  • Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
    Patent number: 9987315
    Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: June 5, 2018
    Assignee: The University of Western Ontario
    Inventors: Grant McFadden, John Barrett, Marianne Stanford
  • Myxoma virus mutants for cancer treatment
    Patent number: 9980994
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: May 29, 2018
    Assignee: ROBARTS RESEARCH INSTITUTE
    Inventors: John W. Barrett, Grant McFadden
  • MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT
    Publication number: 20160136212
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: JOHN W. BARRETT, GRANT MCFADDEN
  • USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT
    Publication number: 20140134134
    Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.
    Type: Application
    Filed: October 9, 2013
    Publication date: May 15, 2014
    Inventors: GRANT MCFADDEN, JOHN BARRETT, MARIANNE STANFORD
  • MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT
    Publication number: 20130336930
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Application
    Filed: August 19, 2013
    Publication date: December 19, 2013
    Applicant: ROBARTS RESEARCH INSTITUTE
    Inventors: John W. BARRETT, Grant MCFADDEN
  • Myxoma virus mutants for cancer treatment
    Patent number: 8512713
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: August 20, 2013
    Assignee: Robarts Research Institute
    Inventors: John W. Barrett, Grant McFadden
  • Nucleic acid molecules and polypeptides for immune modulation
    Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Immunomodulatory protein and useful embodiments thereof
    Patent number: 8227569
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 24, 2012
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
    Patent number: 8227440
    Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: July 24, 2012
    Assignee: Robarts Research Institute
    Inventors: Grant McFadden, John C. Bell
  • USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT
    Publication number: 20110195050
    Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.
    Type: Application
    Filed: August 4, 2010
    Publication date: August 11, 2011
    Applicant: ROBARTS RESEARCH INSTITUTE
    Inventors: Grant McFadden, John Barrett, Marianne Stanford
  • MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT
    Publication number: 20110158945
    Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.
    Type: Application
    Filed: June 1, 2007
    Publication date: June 30, 2011
    Applicant: ROBARTS RESEARCH INSTITUTE
    Inventors: John W. Barrett, Grant McFadden
  • NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION
    Publication number: 20110064757
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Application
    Filed: May 7, 2009
    Publication date: March 17, 2011
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • IMMUNOMODULATORY PROTEIN AND USEFUL EMBODIMENTS THEREOF
    Publication number: 20100331524
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 30, 2010
    Applicant: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Immunomodulatory protein and useful embodiments thereof
    Patent number: 7718368
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 18, 2010
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION
    Publication number: 20090317362
    Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.
    Type: Application
    Filed: August 28, 2009
    Publication date: December 24, 2009
    Applicant: WELLSTAT BIOLOGICS CORPORATION
    Inventors: Grant McFadden, John C. Bell
  • Nucleic acid molecules and polypeptides for immune modulation
    Patent number: 7585507
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: September 8, 2009
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Karim Essani